camostat has been researched along with Disease Models, Animal in 19 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Previously, we reported that a synthetic serine protease inhibitor, camostat mesilate (CM), mitigated hypertension and proteinuria in rodent disease models." | 8.02 | A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats. ( Adachi, M; Deng, Q; Hayata, M; Iwata, Y; Izumi, Y; Kakizoe, Y; Kitamura, K; Kuwabara, T; Miyasato, Y; Miyoshi, T; Mizumoto, T; Morinaga, J; Mukoyama, M; Nakagawa, T; Sakai, Y; Tomita, K; Uchimura, K, 2021) |
| "Camostat mesilate (CM), an oral protease inhibitor, has been used clinically for the treatment of chronic pancreatitis in Japan." | 7.73 | Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. ( Arita, Y; Fujimori, N; Gibo, J; Hisano, T; Inoue, M; Ito, T; Kawabe, K; Nawata, H; Oono, T, 2005) |
| "Camostat has a beneficial effect on pancreatic fibrosis induced by the administration of a SOD inhibitor, which inhibits the proliferation and activation of PSC." | 7.73 | Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats. ( Emori, Y; Ichimura, M; Koide, N; Matsumura, N; Mizushima, T; Ochi, K; Shinji, T; Shirahige, A; Tanimoto, M; Tanioka, H, 2005) |
| "An oral protease inhibitor, camostat mesilate (CM) has been used clinically for chronic pancreatitis (CP) in Japan, but it lacks enough scientific evidence of its effectiveness." | 7.71 | Effect of camostat mesilate on the expression of pancreatitis-associated protein (PAP), p8, and cytokines in rat spontaneous chronic pancreatitis. ( Iovanna, JL; Motoo, Y; Sawabu, N; Su, SB; Xie, MJ, 2001) |
| "An experimental model of chronic pancreatitis was induced by a retrograde injection of a viscous solution consisting of zein-oleic acid-linoleic acid (0." | 7.70 | Pathophysiologic studies of experimental chronic pancreatitis in rats induced by injection of zein-oleic acid-linoleic acid solution into the pancreatic duct. ( Kashima, K; Kataoka, K; Sakagami, J; Sasaki, T; Yorizumi, H, 1998) |
| " Previously, we reported that a synthetic serine protease inhibitor, camostat mesilate (CM), mitigated hypertension and proteinuria in rodent disease models." | 4.02 | A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats. ( Adachi, M; Deng, Q; Hayata, M; Iwata, Y; Izumi, Y; Kakizoe, Y; Kitamura, K; Kuwabara, T; Miyasato, Y; Miyoshi, T; Mizumoto, T; Morinaga, J; Mukoyama, M; Nakagawa, T; Sakai, Y; Tomita, K; Uchimura, K, 2021) |
| "Camostat mesilate (CM), an oral protease inhibitor, has been used clinically for the treatment of chronic pancreatitis in Japan." | 3.73 | Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. ( Arita, Y; Fujimori, N; Gibo, J; Hisano, T; Inoue, M; Ito, T; Kawabe, K; Nawata, H; Oono, T, 2005) |
| "Camostat has a beneficial effect on pancreatic fibrosis induced by the administration of a SOD inhibitor, which inhibits the proliferation and activation of PSC." | 3.73 | Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats. ( Emori, Y; Ichimura, M; Koide, N; Matsumura, N; Mizushima, T; Ochi, K; Shinji, T; Shirahige, A; Tanimoto, M; Tanioka, H, 2005) |
| "An oral protease inhibitor, camostat mesilate (CM) has been used clinically for chronic pancreatitis (CP) in Japan, but it lacks enough scientific evidence of its effectiveness." | 3.71 | Effect of camostat mesilate on the expression of pancreatitis-associated protein (PAP), p8, and cytokines in rat spontaneous chronic pancreatitis. ( Iovanna, JL; Motoo, Y; Sawabu, N; Su, SB; Xie, MJ, 2001) |
| "An experimental model of chronic pancreatitis was induced by a retrograde injection of a viscous solution consisting of zein-oleic acid-linoleic acid (0." | 3.70 | Pathophysiologic studies of experimental chronic pancreatitis in rats induced by injection of zein-oleic acid-linoleic acid solution into the pancreatic duct. ( Kashima, K; Kataoka, K; Sakagami, J; Sasaki, T; Yorizumi, H, 1998) |
| "The effect of methylcarbonylmethyl 2(S)-14-(4-guanidino-benzoyloxy) phenyl] propionate methanesulfonate (TT-S24) on experimental pancreatitis in rats was examined in comparison with that of camostat." | 3.70 | Effect of methylcarbonylmethyl 2(S)-[4-(4-guanidino-benzoyloxy)phenyl] propionate methanesulfonate (TT-S24) on experimental pancreatitis in rats. ( Abe, S; Kamei, C; Tagami, H; Tanaka, I; Yoshida, Y, 1998) |
| "The effect of oral administration of protease inhibitor (camostat) on pancreatic morphology and exocrine function (conscious rat model) was investigated using WBN/Kob rats with spontaneous chronic pancreatitis." | 3.69 | Effect of oral administration of protease inhibitor on pancreatic exocrine function in WBN/Kob rats with chronic pancreatitis. ( Atomi, Y; Kobori, O; Kuroda, A; Muto, T; Sugiyama, M; Wada, N, 1996) |
| "Effects of a new cholecystokinin (CCK)A-receptor antagonist, T-0632 [sodium (S)-1-(2-fluorophenyl)-2, 3-dihydro-3-[(3-isoquinolinylcarbonyl) amino]-6-methoxy-2-oxo-1H-indole-3-propanoate], on caerulein-induced and pancreatic duct ligation-induced pancreatitis models were studied and compared with the CCKA-receptor antagonist loxiglumide and the orally active protease inhibitor camostate, respectively." | 3.69 | Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. ( Endo, T; Kume, E; Nagasaki, M; Shikano, T; Taniguchi, H; Yomota, E, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 7 (36.84) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Shapira, T | 1 |
| Monreal, IA | 1 |
| Dion, SP | 1 |
| Buchholz, DW | 1 |
| Imbiakha, B | 1 |
| Olmstead, AD | 1 |
| Jager, M | 1 |
| Désilets, A | 1 |
| Gao, G | 1 |
| Martins, M | 1 |
| Vandal, T | 1 |
| Thompson, CAH | 1 |
| Chin, A | 1 |
| Rees, WD | 1 |
| Steiner, T | 1 |
| Nabi, IR | 1 |
| Marsault, E | 1 |
| Sahler, J | 1 |
| Diel, DG | 1 |
| Van de Walle, GR | 1 |
| August, A | 1 |
| Whittaker, GR | 1 |
| Boudreault, PL | 1 |
| Leduc, R | 1 |
| Aguilar, HC | 1 |
| Jean, F | 1 |
| Uno, Y | 1 |
| Mizumoto, T | 2 |
| Kakizoe, Y | 2 |
| Nakagawa, T | 2 |
| Iwata, Y | 1 |
| Miyasato, Y | 2 |
| Uchimura, K | 2 |
| Adachi, M | 2 |
| Deng, Q | 1 |
| Hayata, M | 2 |
| Morinaga, J | 2 |
| Miyoshi, T | 2 |
| Izumi, Y | 1 |
| Kuwabara, T | 1 |
| Sakai, Y | 2 |
| Tomita, K | 1 |
| Kitamura, K | 2 |
| Mukoyama, M | 2 |
| Li, K | 1 |
| Meyerholz, DK | 1 |
| Bartlett, JA | 1 |
| McCray, PB | 1 |
| Jia, D | 1 |
| Yamamoto, M | 1 |
| Otsuki, M | 2 |
| Narita, Y | 1 |
| Ueda, M | 1 |
| Kadowaki, D | 1 |
| Hirata, S | 1 |
| Gibo, J | 1 |
| Ito, T | 1 |
| Kawabe, K | 1 |
| Hisano, T | 1 |
| Inoue, M | 1 |
| Fujimori, N | 1 |
| Oono, T | 1 |
| Arita, Y | 1 |
| Nawata, H | 1 |
| Emori, Y | 1 |
| Mizushima, T | 1 |
| Matsumura, N | 1 |
| Ochi, K | 1 |
| Tanioka, H | 1 |
| Shirahige, A | 1 |
| Ichimura, M | 1 |
| Shinji, T | 1 |
| Koide, N | 1 |
| Tanimoto, M | 1 |
| Nagashio, Y | 1 |
| Watanapa, P | 1 |
| Williamson, RC | 1 |
| Sugiyama, M | 1 |
| Kobori, O | 1 |
| Atomi, Y | 1 |
| Wada, N | 1 |
| Kuroda, A | 1 |
| Muto, T | 1 |
| Lee, MG | 1 |
| Kim, KH | 1 |
| Park, KY | 1 |
| Kim, JS | 1 |
| Taniguchi, H | 1 |
| Yomota, E | 1 |
| Kume, E | 1 |
| Shikano, T | 1 |
| Endo, T | 1 |
| Nagasaki, M | 1 |
| Kataoka, K | 1 |
| Sasaki, T | 1 |
| Yorizumi, H | 1 |
| Sakagami, J | 1 |
| Kashima, K | 1 |
| Tagami, H | 1 |
| Abe, S | 1 |
| Yoshida, Y | 1 |
| Tanaka, I | 1 |
| Kamei, C | 1 |
| Su, SB | 1 |
| Motoo, Y | 1 |
| Iovanna, JL | 1 |
| Xie, MJ | 1 |
| Sawabu, N | 1 |
| Kamiyasu, K | 1 |
| Awata, H | 1 |
| Inoshiri, S | 1 |
| Doi, A | 1 |
| Omawari, N | 1 |
| Okegawa, T | 1 |
| Kawasaki, A | 1 |
| Shinomiya, K | 1 |
| Tanaka, M | 1 |
| Suzuki, Y | 1 |
| Redmond, HP | 1 |
| Leahy, AL | 1 |
| Keane, FB | 1 |
| Tanner, WA | 1 |
2 reviews available for camostat and Disease Models, Animal
| Article | Year |
|---|---|
Action of antiproteases on fibrosis in experimental chronic pancreatitis.
Topics: Animals; Disease Models, Animal; Esters; Fibrosis; Gabexate; Guanidines; Pancreatitis, Chronic; Prot | 2007 |
Experimental pancreatic hyperplasia and neoplasia: effects of dietary and surgical manipulation.
Topics: Animals; Cricetinae; Diet; Disease Models, Animal; Energy Intake; Esters; Flour; Gabexate; Glycine m | 1993 |
17 other studies available for camostat and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.
Topics: Animals; COVID-19; Disease Models, Animal; Humans; Mice; Mice, Transgenic; SARS-CoV-2; Serine Endope | 2022 |
Camostat mesilate therapy for COVID-19.
Topics: Animals; Coronavirus Infections; COVID-19; Disease Models, Animal; Esters; Gabexate; Guanidines; Jap | 2020 |
A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats.
Topics: Animals; Apoptosis; Cells, Cultured; Disease Models, Animal; Esters; Guanidines; Hypertension; Male; | 2021 |
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Topics: Angiotensin-Converting Enzyme 2; Animals; Benzamidines; Cells, Cultured; COVID-19 Drug Treatment; Di | 2021 |
Effect of endogenous cholecystokinin on the course of acute pancreatitis in rats.
Topics: Administration, Oral; Animals; Biomarkers; Bombesin; Cell Proliferation; Cholecystokinin; Disease Mo | 2015 |
Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazol | 2016 |
Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity.
Topics: Animals; Cell Proliferation; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Dru | 2005 |
Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats.
Topics: Administration, Oral; Animals; Disease Models, Animal; Ditiocarb; Drug Administration Schedule; Este | 2005 |
Effect of oral administration of protease inhibitor on pancreatic exocrine function in WBN/Kob rats with chronic pancreatitis.
Topics: Administration, Oral; Animals; Cholecystokinin; Chronic Disease; Disease Models, Animal; Esters; Gab | 1996 |
Evaluation of anti-influenza effects of camostat in mice infected with non-adapted human influenza viruses.
Topics: Adaptation, Physiological; Amantadine; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; | 1996 |
Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Disease Models, Animal; Dogs; Esters; Female; Gabexate | 1997 |
Pathophysiologic studies of experimental chronic pancreatitis in rats induced by injection of zein-oleic acid-linoleic acid solution into the pancreatic duct.
Topics: Amylases; Animals; Blood Glucose; Body Weight; Chronic Disease; Disease Models, Animal; Esters; Gabe | 1998 |
Effect of methylcarbonylmethyl 2(S)-[4-(4-guanidino-benzoyloxy)phenyl] propionate methanesulfonate (TT-S24) on experimental pancreatitis in rats.
Topics: Amylases; Animals; Ceruletide; Disease Models, Animal; Esters; Gabexate; Guanidines; Male; Pancreati | 1998 |
Effect of camostat mesilate on the expression of pancreatitis-associated protein (PAP), p8, and cytokines in rat spontaneous chronic pancreatitis.
Topics: Acute-Phase Proteins; Animals; Antigens, Neoplasm; Basic Helix-Loop-Helix Transcription Factors; Bio | 2001 |
[Effects of FOY-305 on post-operative reflux esophagitis in rats (I). Effects of FOY-305 on reflux esophagitis after total gastrectomy in rats].
Topics: Alginates; Animals; Body Weight; Cimetidine; Disease Models, Animal; Esophagitis, Peptic; Esters; Ga | 1991 |
Effect of FOY-305 (Camostate) on severe acute pancreatitis in two experimental animal models.
Topics: Acute Disease; Animals; Disease Models, Animal; Esters; Gabexate; Guanidines; Pancreatitis; Rats; Ra | 1989 |